CD47 and acute myeloid leukemia: Based on preclinical investigations, it is assumed that these novel anti-CD47 mAbs impede CD47-SIRPα interactions leading to macrophage-mediated phagocytosis of B-NHL and AML cells, including LSC cells (118, 119).